MIPSS-ET: Mutation-Enhanced International Prognostic Scoring System for Essential Thrombocythemia
What is MIPSS-ET?
MIPSS-ET is a mutation-enhanced prognostic scoring system that integrates genetic mutations (particularly spliceosome and TP53 mutations) with clinical variables to predict overall survival and disease progression in essential thrombocythemia, providing superior risk stratification compared to conventional scoring systems like IPSET-thrombosis. 1
Risk Stratification Components
MIPSS-ET incorporates both molecular and clinical risk factors to create a three-tiered risk classification:
Molecular Risk Factors (High-Risk Mutations)
- Spliceosome mutations: SF3B1, SRSF2, U2AF1 (adversely affect overall survival and predict myelofibrosis-free survival)
- TP53 mutations: Predict leukemic transformation in ET
- These "adverse mutations" occur in approximately 10% of ET patients 1
Clinical Risk Factors
The system confirmed independent survival effects of:
- Age >60 years (hazard ratio 6.6)
- Male sex (HR 1.8)
- Leukocytosis ≥11 × 10⁹/L (HR 1.6)
- Adverse mutations (HR 2.4) 1
Three-Tiered Risk Classification
MIPSS-ET uses hazard ratio-based risk point allocation to stratify patients into:
- Low risk
- Intermediate risk
- High risk
The system was validated in two independent cohorts (Mayo Clinic and University of Florence) totaling 502 ET patients and demonstrated superior performance to conventional scoring systems 1.
How MIPSS-ET Guides Treatment
Distinction from IPSET-Thrombosis
While IPSET-thrombosis remains the primary tool for predicting thrombotic risk and guiding cytoreductive therapy decisions 2, MIPSS-ET serves a complementary but distinct purpose:
IPSET-thrombosis (for thrombosis risk stratification):
- Age >60 years (1 point)
- Cardiovascular risk factors (1 point)
- Previous thrombosis (2 points)
- JAK2V617F mutation (2 points)
- Score 0-1 = low risk; 2 = intermediate; ≥3 = high risk 2
MIPSS-ET (for survival and disease progression):
- Identifies patients at risk for fibrotic progression through spliceosome mutations
- Predicts leukemic transformation through TP53 mutations
- Provides overall survival estimates 1
Treatment Algorithm Based on Risk Stratification
High-Risk Disease (IPSET-thrombosis ≥3)
Initiate cytoreductive therapy immediately with:
- First-line: Hydroxyurea OR pegylated interferon-α (rINFα) 2
- Plus: Low-dose aspirin (81-100 mg daily) 2, 3
Intermediate-Risk Disease (IPSET-thrombosis = 2)
Add low-dose aspirin when:
- Age ≥60 years, OR
- Uncontrolled cardiovascular risk factors, OR
- JAK2V617F mutation present 2
Consider cytoreductive therapy if:
- Platelet count >1500 × 10⁹/L
- Progressive splenomegaly
- Uncontrolled systemic symptoms 2
Low-Risk Disease (IPSET-thrombosis 0-1)
Observation alone unless:
- Microvascular symptoms present (then add aspirin)
- Cardiovascular risk factors, age ≥60, or JAK2V617F (then add aspirin) 2
Special Molecular Considerations
If MIPSS-ET identifies high-risk mutations:
- Spliceosome mutations (SF3B1, SRSF2, U2AF1): Closer monitoring for myelofibrosis progression; consider earlier intervention
- TP53 mutations: Enhanced surveillance for leukemic transformation; may influence timing of more aggressive therapies 1
CALR-mutated patients: Exercise caution with antiplatelet therapy—associated with higher bleeding risk without thrombosis benefit 2
Critical Pitfalls to Avoid
Do not use anagrelide as first-line therapy: The European LeukemiaNet panel did not reach consensus on anagrelide for first-line use due to insufficient evidence quality and unfavorable risk-benefit ratio 2
Avoid aspirin in CALR-mutated patients without JAK2: Retrospective data show increased bleeding without thrombosis reduction 2
Do not withhold cytoreduction in patients who turn 60: Age 60 is an absolute indication to start cytoreductive therapy regardless of other factors 2
Recognize triple-negative ET: 10-15% of ET patients lack JAK2, CALR, or MPL mutations and may have different risk profiles 4
Second-Line Therapy
When hydroxyurea fails (intolerance or refractoriness):
- Anagrelide OR pegylated interferon-α are recommended second-line options 2
- Prefer interferon in young patients requiring long-term treatment 2
Clinical Integration
In practice, use both systems:
- IPSET-thrombosis determines immediate treatment decisions (cytoreduction yes/no, aspirin yes/no)
- MIPSS-ET provides prognostic information for counseling, surveillance intensity, and potential future therapeutic interventions including consideration for clinical trials or stem cell transplantation in those with high-risk mutations 1, 5
The integration of molecular profiling through MIPSS-ET represents an evolution beyond traditional age and thrombosis history-based stratification, allowing for more personalized risk assessment and potentially earlier intervention in molecularly high-risk patients 1, 6.